Health Care·Pharmaceuticals·$277.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.52 | N/A | -3.18% |
management commentary, guidance changes, and full analysis available with Pro.
| -3.18% |
Tone: Cautiously Optimistic
Overall, management expressed a cautious outlook due to market conditions but remains committed to advancing their product pipeline.
Management highlighted ongoing challenges in the market.
They emphasized a focus on innovation and pipeline development.
The earnings report indicates that Novartis faced some headwinds, resulting in a slight miss on EPS. The stock reacted negatively, dropping 1.33%. Investors may be concerned about the lack of guidance and the challenges mentioned by management, which could impact future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CADENCE DESIGN SYS I
Apr 26, 2021